Brender Jean D, Kelley Katherine E, Werler Martha M, Langlois Peter H, Suarez Lucina, Canfield Mark A
Texas A&M Health Science Center, School of Rural Public Health, College Station, Texas.
Birth Defects Res A Clin Mol Teratol. 2011 Apr;91(4):258-64. doi: 10.1002/bdra.20808. Epub 2011 Apr 6.
Experimental evidence indicates that certain drugs, that are secondary or tertiary amines or amides, form N-nitroso compounds in the presence of nitrite in an acidic environment. Nitrosatable drugs have been associated with birth defects in a few epidemiologic studies. This study describes the prevalence and patterns of nitrosatable drug use among U.S. women during early pregnancy and examines maternal factors associated with such use.
Data were analyzed from the National Birth Defects Prevention Study and included 6807 mothers who gave birth to babies without major congenital malformations during 1997 to 2005. Information was collected by telephone interview about medication use, demographic factors, and maternal health. Drugs taken during the first trimester were classified according to nitrosatability, amine and amide functional groups, and primary indication of use.
Approximately 24% of the women took one or more nitrosatable drugs during the first trimester, including 12.4%, 12.2%, and 7.6% who respectively took secondary amines, tertiary amines, or amides. Five of the ten most commonly taken drugs were available over the counter. Women who were non-Hispanic white (29.5%), with 1 year or more college education (27.3%) or 40 years or older (28.8%) had the highest prevalence of use. Supplemental vitamin C, an inhibitor of nitrosation, was not taken by 41.6% and 19.3% of nitrosatable drug users during the first and second months of pregnancy, respectively.
In this U.S. population, ingestion of drugs classified as nitrosatable was common during the first trimester of pregnancy, especially among non-Hispanic white, more educated, and older mothers.
实验证据表明,某些仲胺或叔胺类或酰胺类药物在酸性环境中与亚硝酸盐共存时会形成N-亚硝基化合物。在一些流行病学研究中,可亚硝化的药物与出生缺陷有关。本研究描述了美国早孕妇女中可亚硝化药物的使用情况及模式,并探讨了与此类使用相关的母体因素。
对国家出生缺陷预防研究的数据进行分析,纳入了1997年至2005年期间分娩的无重大先天性畸形婴儿的6807名母亲。通过电话访谈收集了用药情况、人口统计学因素和母体健康信息。孕早期服用的药物根据可亚硝化性、胺和酰胺官能团以及主要使用指征进行分类。
约24%的妇女在孕早期服用了一种或多种可亚硝化药物,其中分别有12.4%、12.2%和7.6%的妇女服用了仲胺、叔胺或酰胺。十种最常用药物中有五种是非处方药。非西班牙裔白人妇女(29.5%)、接受过一年或以上大学教育的妇女(27.3%)或40岁及以上的妇女(28.8%)的使用率最高。分别有41.6%和19.3%的可亚硝化药物使用者在怀孕的第一个月和第二个月未服用亚硝化抑制剂补充维生素C。
在美国人群中,孕期头三个月摄入可亚硝化药物的情况很常见,尤其是在非西班牙裔白人、受教育程度较高和年龄较大的母亲中。